See more : PT Trias Sentosa Tbk (TRST.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Olympus Corporation (OCPNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olympus Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Agricultural Bank of China Limited (EK7.VI) Income Statement Analysis – Financial Results
- Penpower Technology LTD. (5211.TWO) Income Statement Analysis – Financial Results
- Oxford BioDynamics Plc (OBD.L) Income Statement Analysis – Financial Results
- Mahalaxmi Rubtech Limited (MHLXMIRU.NS) Income Statement Analysis – Financial Results
- Acon Optics Communications Inc. (6820.TWO) Income Statement Analysis – Financial Results
Olympus Corporation (OCPNF)
About Olympus Corporation
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 936.21B | 881.92B | 750.12B | 730.54B | 755.23B | 793.86B | 786.50B | 740.56B | 804.58B | 764.67B | 713.29B | 743.85B | 848.55B | 847.11B | 883.09B | 980.80B | 1,128.88B | 1,061.79B | 978.13B | 813.54B | 633.62B | 564.34B | 528.42B | 466.70B | 428.65B |
Cost of Revenue | 311.09B | 319.23B | 274.13B | 302.56B | 310.67B | 314.16B | 305.39B | 292.99B | 270.10B | 274.82B | 272.83B | 365.65B | 464.74B | 459.42B | 474.84B | 519.58B | 619.40B | 611.50B | 619.90B | 516.47B | 335.05B | 293.53B | 308.64B | 271.44B | 0.00 |
Gross Profit | 625.12B | 562.70B | 475.99B | 427.99B | 444.56B | 479.70B | 481.11B | 447.57B | 534.48B | 489.85B | 440.46B | 378.20B | 383.81B | 387.69B | 408.24B | 461.22B | 509.48B | 450.28B | 358.23B | 297.07B | 298.57B | 270.81B | 219.78B | 195.26B | 428.65B |
Gross Profit Ratio | 66.77% | 63.80% | 63.46% | 58.58% | 58.86% | 60.43% | 61.17% | 60.44% | 66.43% | 64.06% | 61.75% | 50.84% | 45.23% | 45.77% | 46.23% | 47.03% | 45.13% | 42.41% | 36.62% | 36.52% | 47.12% | 47.99% | 41.59% | 41.84% | 100.00% |
Research & Development | 0.00 | 76.87B | 85.30B | 23.20B | 91.60B | 94.00B | 89.50B | 79.18B | 81.42B | 74.10B | 66.80B | 63.38B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 473.23B | 420.55B | 357.51B | 357.03B | 381.17B | 437.51B | 426.60B | 397.70B | 430.77B | 398.89B | 367.01B | 343.12B | 348.29B | 0.00 | 0.00 | 0.00 | 396.86B | 351.55B | 295.71B | 273.92B | 235.57B | 208.47B | 177.50B | 159.76B | 0.00 |
Selling & Marketing | 0.00 | -113.84B | -116.18B | -57.08B | -129.81B | -123.98B | -119.27B | -30.92B | -82.17B | 42.91B | 41.89B | 39.95B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 473.23B | 306.70B | 241.33B | 299.95B | 251.36B | 313.53B | 307.33B | 366.78B | 348.60B | 398.89B | 367.01B | 343.12B | 348.29B | 0.00 | 0.00 | 0.00 | 396.86B | 351.55B | 295.71B | 273.92B | 235.57B | 208.47B | 177.50B | 159.76B | 0.00 |
Other Expenses | 108.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 79.18B | -1.66B | -7.80B | -9.51B | -10.10B | -7.66B | -6.50B | -5.42B | -5.73B | -6.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 581.53B | 383.57B | 326.63B | 323.15B | 342.96B | 407.53B | 396.83B | 366.78B | 430.02B | 398.89B | 367.01B | 343.12B | 348.29B | 349.31B | 348.10B | 426.64B | 396.86B | 351.55B | 295.71B | 273.92B | 235.57B | 208.47B | 177.50B | 159.76B | 0.00 |
Cost & Expenses | 892.61B | 702.80B | 600.77B | 625.71B | 653.63B | 721.69B | 702.22B | 659.77B | 700.11B | 673.71B | 639.84B | 708.77B | 813.03B | 808.73B | 822.94B | 946.22B | 1,016.25B | 963.06B | 915.60B | 790.39B | 570.63B | 502.00B | 486.13B | 431.21B | 0.00 |
Interest Income | 2.56B | 3.70B | 1.01B | 817.00M | 1.28B | 1.30B | 1.13B | 774.00M | 1.09B | 732.00M | 1.07B | 1.05B | 931.00M | 894.00M | 1.12B | 2.42B | 3.20B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 10.31B | 6.03B | 5.14B | 4.27B | 4.41B | 5.03B | 7.05B | 8.58B | 7.89B | 8.92B | 11.47B | 13.94B | 14.03B | 12.74B | 12.41B | 16.19B | 13.91B | 11.26B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 65.94B | 66.74B | 64.62B | 59.94B | 68.31B | 58.67B | 52.91B | 54.29B | 49.78B | 50.64B | 46.31B | 43.58B | 46.07B | 46.44B | 58.27B | 146.26B | 45.60B | 38.27B | 32.70B | 29.76B | 24.25B | 16.86B | 23.70B | 18.25B | 0.00 |
EBITDA | 112.10B | 238.83B | 233.17B | 160.81B | 158.29B | 119.18B | 132.63B | 135.08B | 154.24B | 142.35B | 119.75B | 76.67B | 50.60B | 79.12B | 115.80B | 180.85B | 154.12B | 136.34B | 95.22B | 52.91B | 87.25B | 79.20B | 65.98B | 53.74B | 428.65B |
EBITDA Ratio | 11.97% | 27.88% | 28.53% | 22.55% | 22.50% | 16.48% | 17.44% | 18.24% | 19.17% | 17.21% | 15.24% | 9.20% | 8.81% | 9.73% | 13.11% | 18.44% | 13.52% | 12.84% | 11.03% | 7.84% | 13.76% | 14.95% | 13.02% | 12.55% | 100.00% |
Operating Income | 43.60B | 179.13B | 149.36B | 104.84B | 101.60B | 72.17B | 84.28B | 80.79B | 104.46B | 90.96B | 73.45B | 35.08B | 35.52B | 38.38B | 60.15B | 34.59B | 112.62B | 98.73B | 62.52B | 23.15B | 63.00B | 62.35B | 42.28B | 35.50B | 428.65B |
Operating Income Ratio | 4.66% | 20.31% | 19.91% | 14.35% | 13.45% | 9.09% | 10.72% | 10.91% | 12.98% | 11.90% | 10.30% | 4.72% | 4.19% | 4.53% | 6.81% | 3.53% | 9.98% | 9.30% | 6.39% | 2.85% | 9.94% | 11.05% | 8.00% | 7.61% | 100.00% |
Total Other Income/Expenses | -7.74B | -4.81B | -7.66B | -5.18B | -14.99B | -52.05B | -7.62B | -14.01B | -33.66B | -82.03B | -57.02B | -15.94B | -45.01B | -18.44B | 26.06B | -125.89B | -18.01B | -25.15B | -19.34B | -17.18B | -2.80B | -19.35B | -21.84B | -13.88B | -428.65B |
Income Before Tax | 35.85B | 181.80B | 140.21B | 76.22B | 86.13B | 20.12B | 76.67B | 62.48B | 70.80B | 8.93B | 16.43B | 19.14B | -9.50B | 19.94B | 86.20B | -91.30B | 94.61B | 73.58B | 43.19B | 5.97B | 60.20B | 42.99B | 20.44B | 21.61B | 0.00 |
Income Before Tax Ratio | 3.83% | 20.61% | 18.69% | 10.43% | 11.40% | 2.53% | 9.75% | 8.44% | 8.80% | 1.17% | 2.30% | 2.57% | -1.12% | 2.35% | 9.76% | -9.31% | 8.38% | 6.93% | 4.42% | 0.73% | 9.50% | 7.62% | 3.87% | 4.63% | 0.00% |
Income Tax Expense | 8.88B | 44.30B | 31.07B | 11.14B | 26.04B | 12.07B | 19.57B | 19.67B | 8.15B | 17.81B | 2.80B | 10.90B | 39.28B | 15.63B | 38.27B | 25.87B | 36.76B | 26.08B | 14.83B | 17.80B | 26.64B | 18.65B | 10.16B | 9.83B | -1.86B |
Net Income | 242.57B | 143.43B | 115.74B | 57.71B | 80.29B | 8.15B | 57.06B | 42.78B | 62.59B | -8.74B | 13.63B | 8.02B | -48.99B | 3.87B | 47.76B | -114.81B | 57.97B | 47.80B | 28.56B | -11.83B | 33.56B | 24.35B | 10.28B | 11.79B | 1.86B |
Net Income Ratio | 25.91% | 16.26% | 15.43% | 7.90% | 10.63% | 1.03% | 7.26% | 5.78% | 7.78% | -1.14% | 1.91% | 1.08% | -5.77% | 0.46% | 5.41% | -11.71% | 5.14% | 4.50% | 2.92% | -1.45% | 5.30% | 4.31% | 1.95% | 2.53% | 0.43% |
EPS | 2.40 | 113.22 | 90.22 | 44.89 | 61.18 | 5.97 | 41.71 | 31.25 | 45.73 | -6.38 | 10.26 | 7.24 | -45.88 | 3.60 | 44.31 | -107.21 | 53.62 | 44.20 | 26.50 | -11.25 | 31.74 | 22.97 | 9.72 | 11.14 | 1.76 |
EPS Diluted | 21.88 | 113.08 | 90.17 | 44.87 | 61.15 | 5.96 | 41.69 | 31.24 | 45.71 | -6.38 | 10.26 | 7.24 | -45.88 | 3.60 | 44.31 | -106.99 | 53.61 | 44.20 | 26.50 | -11.25 | 31.74 | 22.97 | 9.72 | 11.14 | 1.76 |
Weighted Avg Shares Out | 11.09B | 1.27B | 1.28B | 1.29B | 1.31B | 1.37B | 1.37B | 1.37B | 1.37B | 1.37B | 1.33B | 1.11B | 1.07B | 1.07B | 1.08B | 1.07B | 1.08B | 1.08B | 1.08B | 1.05B | 1.06B | 1.06B | 1.06B | 1.06B | 1.06B |
Weighted Avg Shares Out (Dil) | 1.22B | 1.27B | 1.28B | 1.29B | 1.31B | 1.37B | 1.37B | 1.37B | 1.37B | 1.37B | 1.33B | 1.11B | 1.07B | 1.07B | 1.08B | 1.07B | 1.08B | 1.08B | 1.08B | 1.05B | 1.06B | 1.06B | 1.06B | 1.06B | 1.06B |
Olympus Corporation (OLYMY) Q2 2025 Earnings Call Transcript
Olympus Corporation (OLYMY) Q1 2025 Earnings Call Transcript
Olympus Corporation (OLYMY) Q4 2024 Earnings Call Transcript
Olympus Corporation (OLYMY) Q3 2024 Earnings Call Transcript
Olympus Corporation (OCPNF) Q2 2024 Earnings Call Transcript
Olympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility
Olympus Issues Request to Discontinue Use of UHI-4 Insufflator Unit, Except in Cases Where No Alternative is Available
Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
Olympus Corporation (OCPNY) Q3 2023 Earnings Call Transcript
Olympus Corporation (OCPNY) Q3 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports